Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

550
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
550
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

782
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
782
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

39
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
39
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

460
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
460
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

47
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
47
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

65
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
65

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Global heart·2026
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

European heart journal·2026
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Journal of the American College of Cardiology·2026
Same authorSame journal

A Contemporary Perspective on Acute Decompensated Heart Failure Classification: A State-of-the-art Review from an International Expert Group.

Cardiac failure review·2026
Same author

Artificial Intelligence in Biomedical Scientific Publishing.

European heart journal·2026

Related Experiment Video

Updated: Oct 4, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.7K

Endpoints in Heart Failure Drug Development.

Aliza Hussain1, Arunima Misra1, Biykem Bozkurt1,2

  • 1Winters Center for Heart Failure, Cardiology, Baylor College of Medicine and Michael E DeBakey VA Medical Center Houston, TX, US.

Cardiac Failure Review
|February 3, 2022
PubMed
Summary
This summary is machine-generated.

This review examines clinical trial endpoints for heart failure (HF), emphasizing the need for outcomes that reflect patient experience alongside mortality and hospitalizations. It discusses challenges and proposes solutions for developing meaningful cardiovascular endpoints.

Keywords:
Endpointsclinical trialsheart failure

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.5K

Related Experiment Videos

Last Updated: Oct 4, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.7K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

1.5K

Area of Science:

  • Cardiovascular Medicine
  • Clinical Trial Design
  • Health Outcomes Research

Background:

  • Heart failure (HF) presents a significant global health burden, necessitating effective therapeutic strategies.
  • Clinical trial endpoints are critical for evaluating drug and device efficacy in HF management.
  • Current endpoints often focus on mortality and hospitalizations, potentially overlooking patient-reported functional capacity and quality of life.

Purpose of the Study:

  • To review the evolution and definition of cardiovascular endpoints in clinical trials.
  • To discuss study designs incorporating mortality, morbidity, and functional endpoints.
  • To identify challenges and propose future directions for developing effective and meaningful cardiovascular endpoints for all stakeholders.

Main Methods:

  • Literature review summarizing the historical development and current definitions of cardiovascular endpoints.
  • Analysis of study design approaches for integrating diverse outcome measures.
  • Examination of challenges in endpoint selection and validation.

Main Results:

  • Established endpoints like mortality and HF hospitalizations provide robust evidence for regulatory approval.
  • There is a recognized need to integrate patient-reported outcomes (PROs) and functional capacity measures.
  • Current endpoint strategies require refinement to better align with patient and clinician needs.

Conclusions:

  • Developing comprehensive cardiovascular endpoints is essential for effective HF treatment evaluation.
  • Future endpoints should balance objective measures with patient-centered outcomes.
  • Collaboration among patients, physicians, regulators, and sponsors is key to advancing endpoint development.